Multidisciplinary Cancer Investigation
نشریه بین المللی چند تخصصی سرطان
Multidiscip Cancer Investig
Medical Sciences
http://mcijournal.com
1
admin
2476-4922
2538-1911
10.30699/acadpub.mci
en
jalali
1400
4
1
gregorian
2021
7
1
5
3
online
1
fulltext
en
The Efficacy and Safety of Iodine-125 Implantation Combined with Gemcitabine in the Treatment of Advanced Pan- creatic Cancer: A Systematic Review and Meta-analysis
Health Services, Quality of Life and Outcomes
Review Article
<div style="text-align: justify;"><span style="font-size:16px;"><span style="font-family:Times New Roman;"><strong>Int</strong><strong>r</strong><strong>oduction</strong><strong>: </strong>A systematic review and meta-analysis was conducted to assess the efficacy and safety of iodine-125 implantation combined with gemcitabine in the treatment of advanced pancreatic cancer.<br>
<strong>Methods</strong><strong>: </strong>PubMed, Chinese National Knowledge Infrastructure database (CNKI), Cochrane Library, Embase, and Wanfang database through Oct 2020 were searched<br>
for randomized controlled trials (RCTs) and retrospective studies assessing the efficacy<br>
and safety of iodine-125 implantation combined with gemcitabine in the treatment of advanced pancreatic cancer. The main outcome measures included the overall remission [complete response (CR)+partial response (PR)] rate, overall survival (OS), hypofunction of the liver, clinical benefit response (CBR) rate, survival rate, and adverse events.<br>
<strong>Results</strong><strong>: </strong>Totally, 19 studies involving 1496 patients were included in the current systematic review and meta-analysis. The pooled results showed that efficacy and safety of patients treated with Iodine-125 combined with gemcitabine were superior to those undergoing gemcitabine alone: overall remission (CR+PR) rate [odds ratio (OR)=3.10, 95% confidence interval (CI): 2.40, 4.00; P<0.00001], OS [hazard ratio (HR)=0.56, 95% CI: 0.47, 0.68; P<0.00001], hypofunction of liver (OR=1.08, 95% CI: 0.67, 1.74;<br>
P=0.75), CBR rate (OR=3.85, 95% CI: 2.83, 5.22; P<0.00001), survival rate of six months (OR=3.44 95% CI: 1.83, 6.46) and survival rate of 12 months (OR=2.67, 95% CI: 1.68, 4.26). And there was no statistical association in adverse events between the groups.<br>
<strong>Conclusions</strong><strong>: </strong>The combination of iodine-125 seed implantation and gemcitabine significantly prolonged the survival of patients with pancreatic cancer, compared with the gemcitabine alone, indicating a better prognosis.</span></span></div>
Iodine-125, Pancreatic Neoplasms, Meta-Analysis, Gemcitabine
1
12
http://mcijournal.com/browse.php?a_code=A-10-500-2&slc_lang=en&sid=1
Jingxin
Yan
583720460@qq.com
10031947532846003043
10031947532846003043
Yes
Department of Interventional Therapy, Affiliated hospital of Qinghai University, Xining, China & Department of Postgraduate, Qinghai University, Xining, China
Ting
Li
1215946762@qq.com
10031947532846003044
10031947532846003044
No
Department of Orthopedics, Sichuan People's Hospital, Chengdu, China & Department of Postgraduate, Chengdu Medical College, Chengdu, China
Yaxuan
Wang
1627608691@qq.com
10031947532846003045
10031947532846003045
No
Department of Radiology, Chengdu Medical College, Chengdu, China
Hao
Zhu
675050874@qq.com
10031947532846003047
10031947532846003047
No
Department of Ultrasound Medicine, People’s Hospital of Tibet Autonomous Region, Lhasa, China & Department of Postgraduate, Tibet University, Lhasa, China
Ruihong
Liu
949495231@qq,com
10031947532846003048
10031947532846003048
No
Nanchong Central Hospital, North Sichuan Medical College, Nanchong, China
Zhenwu
Lei
qhdxzhenwulei@foxmail.com
10031947532846003049
10031947532846003049
No
Department of Interventional Therapy, Affiliated hospital of Qinghai University, Xining, China
Yingxing
Guo
guoyingxing1962@qq.com
10031947532846003046
10031947532846003046
No
Department of Interventional Therapy, Affiliated hospital of Qinghai University, Xining, China